NO20051794L - Fremgangsmate for fremstilling av epotilonderivater, og nye mellomprodukter for fremgangsmaten, samt fremgangsmater for fremstilling av slike - Google Patents

Fremgangsmate for fremstilling av epotilonderivater, og nye mellomprodukter for fremgangsmaten, samt fremgangsmater for fremstilling av slike

Info

Publication number
NO20051794L
NO20051794L NO20051794A NO20051794A NO20051794L NO 20051794 L NO20051794 L NO 20051794L NO 20051794 A NO20051794 A NO 20051794A NO 20051794 A NO20051794 A NO 20051794A NO 20051794 L NO20051794 L NO 20051794L
Authority
NO
Norway
Prior art keywords
preparation
processes
epothilone derivatives
novel intermediates
optionally substituted
Prior art date
Application number
NO20051794A
Other languages
English (en)
Norwegian (no)
Other versions
NO20051794D0 (no
Inventor
Olivier Loiseleur
Guido Koch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051794(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20051794D0 publication Critical patent/NO20051794D0/no
Publication of NO20051794L publication Critical patent/NO20051794L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/16Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20051794A 2002-09-13 2005-04-12 Fremgangsmate for fremstilling av epotilonderivater, og nye mellomprodukter for fremgangsmaten, samt fremgangsmater for fremstilling av slike NO20051794L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221312.2A GB0221312D0 (en) 2002-09-13 2002-09-13 Organic compounds
PCT/EP2003/010171 WO2004024735A2 (en) 2002-09-13 2003-09-12 A new process for the preparation of epothilone derivatives, new epothilone derivatives as well as new intermediate products for the process and the methods of preparing same

Publications (2)

Publication Number Publication Date
NO20051794D0 NO20051794D0 (no) 2005-04-12
NO20051794L true NO20051794L (no) 2005-04-12

Family

ID=9944042

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051794A NO20051794L (no) 2002-09-13 2005-04-12 Fremgangsmate for fremstilling av epotilonderivater, og nye mellomprodukter for fremgangsmaten, samt fremgangsmater for fremstilling av slike

Country Status (29)

Country Link
US (1) US7470792B2 (enExample)
EP (1) EP1539768B1 (enExample)
JP (1) JP4628102B2 (enExample)
KR (1) KR20050042500A (enExample)
CN (1) CN100522968C (enExample)
AR (1) AR041231A1 (enExample)
AT (1) ATE373663T1 (enExample)
AU (2) AU2003267349B2 (enExample)
BR (1) BR0314263A (enExample)
CA (1) CA2497119C (enExample)
CY (1) CY1107794T1 (enExample)
DE (1) DE60316456T2 (enExample)
DK (1) DK1539768T3 (enExample)
EC (1) ECSP055652A (enExample)
ES (1) ES2290489T3 (enExample)
GB (1) GB0221312D0 (enExample)
IL (1) IL166829A (enExample)
MX (1) MXPA05002785A (enExample)
MY (1) MY140442A (enExample)
NO (1) NO20051794L (enExample)
NZ (1) NZ538612A (enExample)
PE (1) PE20050052A1 (enExample)
PL (1) PL375039A1 (enExample)
PT (1) PT1539768E (enExample)
RU (2) RU2404985C2 (enExample)
SG (1) SG155770A1 (enExample)
TW (1) TWI289563B (enExample)
WO (1) WO2004024735A2 (enExample)
ZA (1) ZA200501008B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004018478A2 (en) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008849A1 (de) * 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
WO1998038192A1 (de) * 1997-02-25 1998-09-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Seitenkettenmodifizierte epothilone
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
AU2795000A (en) * 1998-12-22 2000-07-12 Novartis Ag Epothilone derivatives and their use as antitumor agents
EP1226142A2 (en) 1999-07-22 2002-07-31 Schering Aktiengesellschaft Process for the production of epothiolone b and derivatives as well as intermediate products for this process
US6593115B2 (en) * 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
JP2005500974A (ja) 2000-10-13 2005-01-13 ザ ユニバーシテイ オブ ミシシッピー エポシロン類及び関連類似体の合成
PL374528A1 (en) * 2002-07-31 2005-10-31 Schering Aktiengesellschaft New effector conjugates, process for their production and their pharmaceutical use

Also Published As

Publication number Publication date
EP1539768A2 (en) 2005-06-15
CN100522968C (zh) 2009-08-05
MXPA05002785A (es) 2005-06-03
AU2008203451A1 (en) 2008-08-21
CY1107794T1 (el) 2013-06-19
EP1539768B1 (en) 2007-09-19
RU2404985C2 (ru) 2010-11-27
DE60316456T2 (de) 2008-06-19
JP4628102B2 (ja) 2011-02-09
AR041231A1 (es) 2005-05-11
ECSP055652A (es) 2005-05-30
ATE373663T1 (de) 2007-10-15
CN1681824A (zh) 2005-10-12
RU2008129613A (ru) 2010-01-27
WO2004024735A2 (en) 2004-03-25
BR0314263A (pt) 2005-07-05
TW200413388A (en) 2004-08-01
KR20050042500A (ko) 2005-05-09
US7470792B2 (en) 2008-12-30
WO2004024735A3 (en) 2004-07-22
ZA200501008B (en) 2006-12-27
NZ538612A (en) 2008-01-31
AU2003267349A1 (en) 2004-04-30
NO20051794D0 (no) 2005-04-12
MY140442A (en) 2009-12-31
RU2343155C2 (ru) 2009-01-10
DE60316456D1 (de) 2007-10-31
GB0221312D0 (en) 2002-10-23
PL375039A1 (en) 2005-11-14
ES2290489T3 (es) 2008-02-16
JP2006511469A (ja) 2006-04-06
CA2497119C (en) 2011-08-02
RU2005110925A (ru) 2006-01-20
CA2497119A1 (en) 2004-03-25
AU2003267349B2 (en) 2008-05-01
US20060106073A1 (en) 2006-05-18
IL166829A (en) 2011-01-31
PE20050052A1 (es) 2005-03-28
SG155770A1 (en) 2009-10-29
DK1539768T3 (da) 2008-01-07
HK1078853A1 (en) 2006-03-24
PT1539768E (pt) 2007-12-17
TWI289563B (en) 2007-11-11

Similar Documents

Publication Publication Date Title
NO20081464L (no) 1-heterocyklusulfonyl, 2-aminometyl, 5-(hetero-)aryl subsidiert 1-H-pyrrol-derivater som syresekresjonsinhibitorer
WO2003045929A1 (en) Bicyclic derivative, process for producing the same, and use
EA200601852A1 (ru) Тетрагидрохинолиновые производные и способ их получения
EA200602170A1 (ru) Производные пиперидина, композиции на их основе, способы их применения
NO20080717L (no) Oksimderivat og fremgangsmate for fremstilling av dette
DE60311821D1 (de) Dibenzylaminverbindung und deren medizinische verwendung
NO20065537L (no) Heterosykliske amidforbindelser og anvendelse derav som en MMP-13-inhibitor
CA2213124A1 (en) Benzoyl derivatives
NO20076660L (no) Fremgangsmate for fremstilling av rosuvastatin og mellomprodukter
ÖZDEMİR et al. Novel analogues of 2-pyrazoline: synthesis, characterization, and antimycobacterial evaluation
EP1566384A4 (en) NEW AZOL DERIVATIVES
YU47555B (sh) Derivati tetrahidrobenzimidazola i postupak za njihovo dobijanje
El‐Gaby Syntheses of hitherto unknown Thiazole, Ylidene and Pyridinethione derivatives having a Piperidin‐1‐yl moiety and their use as antimicrobial agents
NO20051794L (no) Fremgangsmate for fremstilling av epotilonderivater, og nye mellomprodukter for fremgangsmaten, samt fremgangsmater for fremstilling av slike
NO20000373D0 (no) Nye cyano-indol serotinin-reopptaks-inhibitorforbindelser, fremgangsmåte for deres fremstilling og farmasoeytiske sammensetninger inneholdende dem
Mashelkar et al. Synthesis of some novel 4-substituted coumarins having potential biological activity (Part III)
HK1077520A1 (zh) 用作p38促细胞分裂原活化蛋白激酶抑制剂的吲哚类衍生物
DK1116719T3 (da) 3-(1-hydroxy-pentyliden)-5-nitro-3H-benzofuran-2-on, fremgangsmåde til fremstilling deraf og anvendelse deraf
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
Abdel-Hafez Synthesis, Antimicrobial Activity of Some New 2-Amino-4-(4′-phenylsulfanyl-phenyl)-thiazole Derivatives and Theoretical Studies of Their Schiff's Base
Kriplani et al. Microwave assisted synthesis of some biologically active benzothiazolotriazine derivatives
Singh et al. The facile and efficient synthesis of novel monocyclic cis-β-lactam conjugates with a 1-methyl-1 H-imidazole-2-thiol nucleus
TW200612912A (en) Benzyloxy derivatives as maob inhibitors
Salvi et al. Synthesis of phthalimido or succinimido-[2-aryl-4-oxo-3-[{2-oxo-2-(phenothiazin-10-yl) ethyl} amino]-1, 3-thiazolidin-5-yl] ethanoate and their antimicrobial activities
Ayyash Synthesis And Characterization Of Some New Quinolin-2 (1H)-Ones And Imidazoles Containing 1, 3, 4-Thiadiazoline Ring Derived From Thiosemicarbazone.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application